NEKTAR THERAPEUTICS Q3 2026 FINANCIAL RESULTS - NEKTAR THERAPEUTICS

Financial Performance:

• Ended Q3 2026 with approximately $953 million in cash and investments; no debt on the balance sheet.
• Projected to end 2026 with >$840 million in cash and investments (above the previous Q2 guidance range of $815–$840 million).
• Q3 non-cash royalty revenue totaled $8.5 million; full-year non-cash royalty revenue expected at ~$38 million.
• Q3 R&D expenses were ~$44 million; full-year R&D expenses projected between $185 million and $200 million (including $5–$10 million in non-cash D&A and stock-based comp).
• Q3 G&A expenses were ~$25 million; full-year G&A expected at ~$65 million.
• Q3 net loss was ~$56 million ($1.63 per share); full-year non-cash interest expense anticipated at ~$28 million.
• Full-year Q3 2026 net loss reflects significant clinical progression costs but maintains a robust liquidity position to fund the Phase 3 program.

Guidance and Future Outlook:

• Phase 3 studies for RESPEG (Atopic Dermatitis) initiated; Alopecia Areata study (Zenith AA) on track to start in December 2026, earlier than the original Q2 2027 estimate.
• First top-line data for Atopic Dermatitis (Zenith AD) expected Summer 2028, with a Biologics License Application (BLA) filing targeted for end of 2029.
• Alopecia Areata (Zenith AA) data expected in 2029.
• Vitiligo proof-of-concept study (N=30) expected to launch in early 2027 with data anticipated late 2027 or early 2028.
• Type 1 Diabetes study (TrialNet) data from the first cohort (18 patients) expected late 2027 or early 2028.
• Management reaffirmed confidence in achieving the broadest possible regulatory label spanning first-line (biologic/JAK naive), second-line, monotherapy, and combination use with topical corticosteroids.

Business Segments and Product Lines:

• RESPEG (Lead Asset): A first-in-class TNFR2 agonist restoring immune balance via Regulatory T-cell (Treg) expansion, distinct from single-pathway cytokine blockers.
• Atopic Dermatitis (Zenith AD Program): Comprises three global Phase 3 studies (ZENITH AD1, AD2, AD3) enrolling ~1,500 patients (ages 12+).
  • AD1: Monotherapy in biologic/JAK inhibitor naive patients.
  • AD2: Adapted to evaluate combination with topical corticosteroids in both naive and experienced patients based on regulatory feedback.
  • AD3: Monotherapy in biologic/JAK inhibitor experienced patients.
• Alopecia Areata (Zenith AA Program): Single global Phase 3 study enrolling ~850 severe-to-very severe patients (ages 12+), expected to start December 2026. Includes a long-term extension for maintenance dosing.
• New Indications: Planned proof-of-concept study in Vitiligo (1.9M US patients) to leverage Treg mechanism; strong mechanistic rationale based on biomarker data showing IL-10 and TGF-beta-1 elevation.
• Pipeline Expansion: Preclinical work continues on a bispecific TNFR2 program (NECTAR-0166) targeting a second undisclosed immune partner.
• Clinical Data Highlights: EADV presentations showed durable hair regrowth in Alopecia Areata off-treatment and sustained skin clearance/itch relief in Atopic Dermatitis with monthly/quarterly maintenance dosing.

Market and Competitive Landscape:

• Atopic Dermatitis: US market estimated at 31 million patients; UK forecast to exceed $30B by 2033. Current biologics target only Type 2/IL-13 pathways; ~50% of patients on existing biologics report inadequate control.
• Competitive Dynamics: Market share shift observed where Dupixent lost new-to-brand starts to novel MOAs (e.g., Nemluvio). Physician surveys indicate 90% would consider starting RESPEG before existing biologics or JAK inhibitors.
• Alopecia Areata: Market forecasted to reach ~$5.2B by 2033. Current JAK inhibitors face safety warnings, daily dosing burdens, and lack of durable responses post-treatment.
• Vitiligo: Underpenetrated market with only 15% seeking treatment; no approved therapies for the broader population, creating a significant unmet need.
• Differentiation: RESPEG targets heterogeneous disease biology by normalizing multiple inflammatory pathways (Th1, Th2, Th17) rather than blocking a single cytokine.

Risks and Challenges:

• Clinical Execution: Dependence on successful enrollment and top-line readouts in Summer 2028 (AD) and 2029 (AA).
• Regulatory Uncertainty: While current regulatory feedback supports the adapted study design, final approval outcomes remain contingent on statistical significance and safety profiles.
• Off-Treatment Durability: The novel "off-treatment" follow-up design in Resolve AD (non-placebo withdrawal) requires validation against established benchmarks (e.g., Dupixent) to prove long-term durability without sham injections.
• Competitive Setbacks: While setbacks in the OX40 class benefit RESPEG, competition remains high with upcoming readouts from STAT6, bispecifics, and trispecifics.
• Commercial Adoption: Need to convince payers and physicians to adopt a novel mechanism in a market dominated by established therapies.

Management Commentary and Tone:

• Tone: Highly confident and optimistic; described Q3 as "transformative" and the company as being in a "great position" with a "robust" Phase 3 plan.
• Strategic Focus: Emphasis on executing the Phase 3 program to bring a disease-modifying therapy to market quickly.
• Team Capabilities: Highlighted the clinical team's ability to accelerate timelines (e.g., Alopecia Areata study start moved to December) as a key asset.
• Market Philosophy: Management explicitly stated they do not view competitor failures as a benefit, citing the large, heterogeneous market size as sufficient for multiple successful therapies.

Analyst Questions and Answers:

• Vitiligo Study Design: Confirmed as an open-label, single-arm proof-of-concept study (approx. 30 patients) leveraging the low placebo effect in vitiligo endpoints; targeting active non-segmental vitiligo patients.
• Resolve AD Off-Treatment Data (Q1 2027): Focus is on 125 patients (110 on RESPEG, 15 placebo) following 52 weeks of treatment. Goal is to validate durability and determine if dosing can reduce to quarterly or semi-annually.
• Zenith AD2 Protocol Change: Driven by feedback from FDA, EMA, and PMDA; adding topical corticosteroid combination arm is standard for global registration (required in Japan) and supports a broad label for experienced patients.
• Enrollment Trends: Enrollment rates are similar between biologic-naive and experienced patient cohorts; full enrollment projected for January 2029 with top-line data in Summer 2028.
• Biomarker Correlations: Early increases in IL-10 and TGF-beta-1 (Week 2) correlate with clinical improvement (Week 16), supporting the Treg mechanism and disease-modifying potential.
• Type 1 Diabetes: TrialNet study enrolled; 18-patient cohort data expected late 2027/early 2028.
• Competitive Landscape: Howard Robin noted that despite potential setbacks in other classes, the Atopic Dermatitis market is large enough to support multiple mechanisms given the 50% failure rate on existing IL-13 therapies.

Other Key Points:

• Biomarker Validation: Mount Sinai substudy confirmed RESPEG's ability to normalize multiple inflammatory pathways (Th1, Th2, Th17, JAK-STAT) and modulate cardiovascular risk markers in blood and skin.
• Durability Evidence: Alopecia Areata data showed hair regrowth maintenance 6 months post-treatment (19% achieving SALT20 off-treatment vs 7% on-treatment SALT10), contrasting sharply with the typical relapse seen after JAK inhibitor discontinuation.
• Dosing Strategy: The program aims to validate quarterly dosing after 24 months and potentially semi-annual dosing for deep responders, addressing a major pain point of daily oral therapies.
• Safety Database: The combined Zenith AD and AA programs will enroll ~2,400 patients, providing a substantial safety database to support registrational approval.